Table 2.
Intraoperative and postoperative findings.
| Non-re-PTx group n = 709 |
Re-PTx group n = 61 |
P value | OR | 95% CI | |||
|---|---|---|---|---|---|---|---|
| Intraoperative results | Maximum diameter of PTG for autograft (mm), mean (SD) | 11.8 (3.4) | 13.2 (3.5) | 0.001 | |||
| Weight of PTG for autograft (mg), mean (SD) | 333.8 (266.0) | 414.9 (241.4) | < 0.001 | ||||
| Number of fragmented parathyroid pieces for autograft, mean (SD) | 29.2 (2.7) | 29.7 (1.9) | 0.087 | ||||
| Postoperative results | Serum albumin level on POD 1 (g/dL), mean (SD) | 3.6 (0.5) | 3.5 (0.5) | 0.131 | |||
| Serum alkaline phosphatase level on POD 1 (U/L), mean (SD) | 451.3 (428.4) | 447.0 (357.8) | 0.687 | ||||
| Serum calcium level on POD 1 (mg/dL), mean (SD) | 10.0 (0.8) | 10.2 (0.6) | 0.726 | ||||
| Serum calcium level corrected by serum albumin level on POD 1 (mg/dL), mean (SD) | 10.4 (0.9) | 10.8 (0.8) | 0.832 | ||||
| Serum phosphorus level on POD 1 (mg/dL), mean (SD) | 6.2 (4.5) | 6.6 (1.6) | 0.028 | ||||
| Serum intact PTH levels on POD 1 (pg/mL), mean (SD) | 14.2 (10.4) | 19.3 (14.3) | 0.012 | ||||
| Hyperplastic pattern of PTG | 0.348 | ||||||
| Diffuse hyperplasia, n (%) | 76 (96.2) | 3 (3.8) | |||||
| Diffuse and nodular hyperplasia, n (%) | 350 (91.4) | 33 (8.6) | |||||
| Nodular hyperplasia, n (%) | 269 (92.1) | 23 (7.9) | |||||
| Thyroid papillary carcinoma diagnosed in the paraffin section, n (%) | 35 (4.9) | 4 (6.5) | 0.580 | 1.351 | 0.464 | 3.937 | |
| Parathyroid carcinoma diagnosed in the paraffin section, n (%) | 0 | 0 | NA | ||||
| Serum intact PTH levels before re-PTx for graft-dependent SHPT (pg/mL), mean (SD) | 459.4 (276.0) | NA | |||||
| Serum intact PTH levels 1 day after re-PTx for graft-dependent SHPT (pg/mL), mean (SD) | 132.7 (160.2) | NA | |||||
| Re-PTx for recurrent SHPT in the neck or mediastinum, n (%) | 10 (1.4%) | 3 (4.9) | 0.076 | ||||
| Postoperative calcium supplementation therapy, n (%) | 709 (100.0) | 61 (100.0) | > 0.999 | NA | NA | NA | |
| Postoperative vitamin D receptor activation therapy, n (%) | 709 (100.0) | 61 (100.0) | > 0.999 | NA | NA | NA | |
| Postoperative calcimimetics therapy, n (%) | 52 (8.0) | 30 (50.0) | < 0.001 | 11.558 | 6.471 | 20.642 | |
| Kidney transplantation after initial PTx, n (%) | 33 (5.0) | 3 (5.0) | > 0.999 | 1.000 | 0.297 | 3.362 | |
| Hypoparathyroidism after initial PTx, n (%) | 331 (46.7) | 0 | < 0.001 | ||||
| Death during the observation period, n (%) | 31 (4.4) | 3 (4.9) | 0.746 | 1.130 | 0.335 | 3.807 | |
| Observation period (months), mean (SD) | 58.7 (53.5) | 68.3 (33.9) | 0.003 | ||||
CI, confidence interval; NA, not accessed; OR, odds ratio; POD 1, postoperative day 1; PTGs, parathyroid glands; PTH, parathyroid hormone; PTx, parathyroidectomy; SD, standard deviation; SHPT, secondary hyperparathyroidism. Bold font indicates statistically significant results.